Authors
Latest:
Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple MyelomaAndrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Latest:
Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer TreatmentWilliam J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Latest:
Dr. Stephenson on the Development of Biomarkers for Prostate CancerAndrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
Latest:
Dr. Jennis on Progress in Implementing Oncology Care ModelAndrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.
Latest:
Proton Therapy: A Path to Improved Outcomes and Quality of LifeAlthough development outlays with proton therapy have decreased, treatment costs remain higher than for conventional radiotherapy, fueling a debate about whether the benefits justify the costs.
Latest:
Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRCAndrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).
Latest:
Dr Kin on Clinical Implications of the FDA Approval of Teclistamab in R/R Multiple MyelomaAndrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.
Latest:
Dr. Ko Discusses the CheckMate-577 TrialAndrew Ko, MD, professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses exciting data from the 2018 Gastrointestinal Cancers Symposium.
Latest:
Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated MelanomaAndrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.
Latest:
Dr. Pecora on JTCC Joining Georgetown Lombardi Cancer ConsortiumAndrew L. Pecora, MD, FACP, CPE, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses John Theurer Cancer Center (JTCC) joining Georgetown Lombardi Cancer Consortium.
Latest:
Dr. Laramore on Genetic Testing in Hematologic CancersAndrew Laramore, MD, Anatomic and Clinical Pathology, Diagnostic Pathology Services, discusses some of the known genes that are tested for in hematologic malignancies.
Latest:
Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate CancerAndrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.
Latest:
Dr. Norden on Cost and Effectiveness of Genomic TestingAndrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.
Latest:
Liquid Biopsy Mania Leaves Questions UnansweredMany physicians are excited by the possibility of following the evolving story of their patients’ cancer no longer through images including PET scans, but through changes in the molecular phenotype of their patients’ tumors.
Latest:
Dr. Pecora on Updated MAIA Data in Multiple MyelomaAndrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.
Latest:
Dr. Allen Discusses CO-1686 as a Treatment for Lung CancerAndrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.
Latest:
Dr. Branagan on Vaccine to Better Protect Myeloma Patients From FluAndrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.
Latest:
NYU Scientist Sees Hope Peeking Through Gloom of GlioblastomaUsing a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.
Latest:
VCU Explores Novel Combos for Solid TumorsStudies conducted at VCU Massey Cancer Center in Richmond, Virginia, over the past 7 years have developed the therapeutic combination of pemetrexed and sorafenib (Nexavar) from the bench to the bedside, and now into phase II clinical trial evaluation.
Latest:
Progress on New Therapies Stirs Hope in SCLCDuring the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.
Latest:
Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate CancerAndrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.
Latest:
Dr. Andrew Chan on Aspirin's Link to Reduced Cancer RiskAndrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.
